The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...
The FDA issued a safety communication today warning of a potential increased risk of seizures tied to certain medications used to treat Parkinson's disease. The agency will require manufacturers of ...
Clinicians should monitor vitamin B6 levels in Parkinson disease patients taking carbidopa/levodopa due to a risk for deficiency-linked seizures. Reports of seizures linked to vitamin B6 deficiency in ...
The study additionally shows sustained and smooth levodopa levels in the blood stream. Laxxon's LXM.5 can achieve such improved bioavailability and levodopa levels due to the sequential release of the ...
Please provide your email address to receive an email when new articles are posted on . Once-daily opicapone 50 mg with carbidopa/levodopa helped achieve and maintain plasma concentrations of levodopa ...
A common drug combo for Parkinson’s disease will require a new FDA warning after the agency flagged 14 cases of seizures in patients using the medications. The agency is mandating (PDF) that ...
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion for Onerji (levodopa/carbidopa, Tanabe Pharma) for the treatment of adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results